Adicet Bio, Inc. (NASDAQ:ACET) Given Consensus Rating of "Moderate Buy" by AnalystsMarket Beat·Aug 24 at 09:14 AMACET-0.89%
Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell TherapyMarket Beat·Aug 11 at 11:04 AMACET-0.89%
Adicet Bio Q2 FY26 net loss widens to $21.4 million; cash and short-term investments total $118.2 millionPUBT·Aug 5 at 04:23 PMACET-0.89%
Adicet Bio (ACET) Projected to Release Quarterly Earnings on ThursdayMarket Beat·Jul 30 at 03:41 AMACET-0.89%BEN+0.49%
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga_article·Jun 25 at 07:05 AMTELA+1.54%PASG+4.39%
Adicet Bio shareholders elect three Class II directors at annual meetingPUBT·Jun 18 at 03:02 PMACET-0.89%
10 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jun 15 at 07:05 AMSSII+3.80%ELTX-3.00%
